Kanellopoulos P

Improving GRPR-targeting peptides for radiotheranostics application: insights from chelator modifications and α-methyl-L tryptophan substitution.

Obeid K, Bezverkhniaia E, Tolmachev V, Orlova A, Kanellopoulos P

EJNMMI Radiopharm Chem 10 (1) 74 [2025-11-13; online 2025-11-13]

Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?

Orlova A, Rybina A, Medvedeva A, ..., Tolmachev V, Chernov V

Pharmaceutics 17 (10) - [2025-10-12; online 2025-10-12]

Reduction of Negative Charge in Mercaptoacetyl-Based Chelators Influences the Biodistribution of Prostate-Specific Membrane Antigen-Targeting Pseudopeptides Labeled with Technetium-99m.

Bezverkhniaia E, Kanellopoulos P, Rosenström U, Tolmachev V, Orlova A

ACS pharmacology & translational science 8 (10) 3600-3612 [2025-10-10; online 2025-09-25]

RM2 and DB15 analogues bearing [177Lu]Lu-DOTAGA via different linkers, as radiotherapeutics: a head-to-head comparative study.

Kanellopoulos P, Bitzios A, Zelepukin I, ..., Tolmachev V, Orlova A

EJNMMI Radiopharm Chem 10 (1) 50 [2025-07-31; online 2025-07-31]

Evaluation of maSSS/maSES-PEG2-RM26 for their potential therapeutic use after labeling with Re-188. Could their [99mTc]Tc-labeled counterparts be used to estimate dosimetry?

Kanellopoulos P, Yu Q, Abouzayed A, ..., Tolmachev V, Orlova A

EJNMMI Radiopharm Chem 10 (1) 3 [2025-01-17; online 2025-01-17]

Evaluation of ABD-Linked RM26 Conjugates for GRPR-Targeted Drug Delivery.

Nagy Á, Abouzayed A, Kanellopoulos P, ..., Orlova A, Eriksson Karlström A

ACS Omega 9 (34) 36122-36133 [2024-08-27; online 2024-08-15]

Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer.

Kanellopoulos P, Bezverkhniaia E, Abouzayed A, ..., Tolmachev V, Orlova A

ACS Omega 9 (16) 18608-18616 [2024-04-23; online 2024-04-10]

GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics.

Obeid K, Kanellopoulos P, Abouzayed A, ..., Maina T, Orlova A

Pharmaceutics 16 (4) - [2024-04-08; online 2024-04-08]

Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m.

Bezverkhniaia E, Kanellopoulos P, Rosenström U, Tolmachev V, Orlova A

Int J Mol Sci 25 (7) - [2024-03-23; online 2024-03-23]

Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA).

Bezverkhniaia E, Kanellopoulos P, Abouzayed A, ..., Tolmachev V, Orlova A

Int J Mol Sci 24 (24) - [2023-12-12; online 2023-12-12]